Pacira BioSciences
PCRX
273 hedge funds and large institutions have $2.67B invested in Pacira BioSciences in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 116 increasing their positions, 83 reducing their positions, and 30 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 83
1.84% more ownership
Funds ownership: 107.74% → 109.57% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less funds holding
Funds holding: 284 → 273 (-11)
5% less capital invested
Capital invested by funds: $2.82B → $2.67B (-$150M)
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
43% less call options, than puts
Call options by funds: $3.31M | Put options by funds: $5.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$55.6M |
| 2 |
Millennium Management
New York
|
+$24.3M |
| 3 |
Jennison Associates
New York
|
+$21.3M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$13.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$35M |
| 2 |
PC
Paulson & Co
New York
|
-$20.4M |
| 3 |
Renaissance Technologies
New York
|
-$11.8M |
| 4 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$11.6M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$8.93M |
PCRX Hedge Fund Activity: Q3 2022 in Review
273 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2022, worth a combined $2.67B — down 5.3% from $2.82B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PCRX and 22 opened new positions — a net loss of 8 holders — while 83 trimmed existing stakes and 116 added.
The largest buyer was Armistice Capital, adding an estimated $55.6M. The largest seller was Macquarie Group, cutting an estimated $35M.
- 273 institutional investors held Pacira BioSciences (PCRX) as of Q3 2022, down from 284 in Q2 2022.
- Funds reported $2.67B of Pacira BioSciences stock for Q3 2022, down 5.3% quarter-over-quarter.
- 22 funds opened new Pacira BioSciences positions in Q3 2022 and 30 closed out, a net change of -8 holders.
- The largest Pacira BioSciences buyer in Q3 2022 was Armistice Capital, an estimated $55.6M added.
- The largest Pacira BioSciences seller in Q3 2022 was Macquarie Group, an estimated $35M sold.
Based on aggregated 13F filings for Q3 2022.